Maintenance lapatinib after first-line chemotherapy in HER1/2-positive metastatic bladder cancer - European Medical Journal

Maintenance lapatinib after first-line chemotherapy in HER1/2-positive metastatic bladder cancer

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University of London, London, UK, discusses the results of a phase 2/3 trial, which evaluated if maintenance therapy with lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, after first-line chemotherapy is associated with clinical benefit in patients with HER1/2-positive metastatic transitional cell carcinoma.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given